Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.

For new or worsening nephropathy there was a nominally significant quantitative interaction with a p-value of 0.0013 due to an inconsistent pattern of treatment effect (U-shaped pattern with lowest HRs of 0.45 and 0.42 in patients without MetS and those fulfilling 4–5 criteria compared to HRs of 0.81 and 0.71 in those fulfilling 2 or 3 criteria, respectively).

also in 7,732 other papers